AI - Based Precision Breast Diagnostics From The Digital Leaders

Have the answer right when you need it. Diagnexia and Stratipath have partnered to bring rapid, cost-effective, and clinically validated AI-based prognostic testing to breast cancer diagnostics across the UK and Europe.

Order Now

The Challenge

Every Patient Should Have Access to Precision Diagnostics

Traditional testing is slow, costly and limited. Current gene expression tests can take 1–2 weeks, cost thousands, and are often inaccessible due to their complexity and cost. This can delay treatment decisions and contribute to health inequities in breast cancer care.

The Solution

Rapid, AI-Powered Prognostic Risk Profiling directly from the H&E slide

Stratipath Breast utilises a single routine H&E-stained slide to classify a Patients tumor into high- or low-risk categories, providing clear cost effective results and reducing the need for expensive molecular testing.

Now available via Diagnexia’s digital pathology platform, it offers:

Fast AI analysis

Once scanned, results are available within minutes

Lower costs

No gene testing or extra lab work needed

Clinical confidence

CE-IVD and UK-Rep compliant

Streamlined workflow

No manual handling or new equipment

How it Works

Diagnexia is there to help whether your lab is digital or not

Utilise your digital Pathology images or let us collect and scan your slides, Diagnexia is there to make sure you have the results ready for MDT.

Upload routine H&E slides
Automated AI analysis by Stratipath
Prognostic result returned in under an hour
Oncologist makes informed treatment decision

Why it Matters

Precision Oncology for Everyone

By removing barriers to prognostic testing, this partnership helps democratize access to personalised cancer care:

  • Quicker treatment decisions
  • Reduced diagnostic bottlenecks
  • Greater equity in access to advanced diagnostics
Stratipath Breast is a natural addition to our portfolio of AI-Based digital pathology solutions. At Diagnexia, we are committed to advancing precision oncology by integrating AI into routine clinical workflows. This partnership allows us to bring Stratipath’s groundbreaking risk stratification technology to more patients and clinicians, reducing delays and improving access to personalised cancer diagnostics.”
Donal O’Shea
CEO, Diagnexia

Who It’s For

Built for Pathology Labs, Hospitals, and Oncology Teams

Whether you're a histopathologist looking to streamline workflows or an oncologist in need of timely prognostic insights, this solution fits seamlessly into your clinical environment—no new infrastructure required.

About the Partners

Digital Leaders of AI - Based Precision Breast Diagnostics

A global leader in AI-powered digital pathology, offering expert diagnostic services and scalable digital workflows.

An AI-driven oncology company delivering cutting-edge precision diagnostics through CE-marked and UK-validated software tools.

Request more information

Want to know more?

Find out how Diagnexia with Stratipath can help your lab, hospital or oncology team.